SYNTHOS RESEARCH

Assurant AIZ

Financial Services · Insurance - Specialty · Synthos Deep Dive · 2026-07-03

$279.48
Watch
Risk 4Growth 6Exponential 3Fair value $290 $220–$355

At a glance

VerdictWatch — systematic Synthos tier
Price (2026-07-02)$279.48 · market cap ~$13.8B
Synthos scores (0–10)Downside Risk 4 · Growth Quality 6 · Exponential Potential 3
Synthos fair value (base case)~$290+4% · full range $220 (bear) – $355 (bull)
Street consensus$285.83 (high $310 / low $246; 11 Buy · 7 Hold · 1 Sell) — context, not our anchor
Valuation14× trailing EPS · 13× FY26E · 12× FY27E · EV/S 1.1× · EV/EBITDA 9.0× · P/B 2.4× · FCF yield ~10.5%
Exponential Potential3/10 · Low — mature specialty insurer, ~12% EPS CAGR that is buyback-aided and not accelerating; no large-TAM catalyst
TechnicalsExtended — $279, at the 52-wk high, RSI(14) 78 (overbought), +41% 12-mo (SPY +21%), above 50/200-DMA
ConvictionLow breadth0 expert voices, 0 traceable claims in the Synthos KB; call rests on fundamentals + quant
Position sizingSatellite value/quality holding, ~1–3%; prefer to add on a pullback off the high
Next catalyst2026-08-04 Q2'26 earnings (Street EPS $5.16)
Single biggest riskCatastrophe volatility in Global Housing — one bad hurricane season swings earnings and book value

One-line thesis. Assurant is a cheap, low-beta, well-managed specialty insurer whose Global Lifestyle engine (phone protection, extended warranties, vehicle plans) compounds steadily and whose Housing arm throws off catastrophe-lumpy but high-return cash — but after a +41% run to a fresh 52-week high with RSI at 78 and management guiding only low-single-digit adjusted EPS growth in 2026, the easy money looks made; this is a Watch to buy on weakness, not a chase.

◆ Synthos call — Watch AIZ is a business we want at a price we don't have — it becomes a Buy below ~$255; until then, do nothing.
Downside Risk (lower = safer)
4/10 · Moderate
Low beta (0.57), net-debt/EBITDA 0.38×, cheap at 14× — but RSI 78 at the 52-wk high and cat-exposed Housing.
Growth Quality
6/10 · High
~12% forward EPS CAGR (buyback-aided), 17% ROE, steady Lifestyle compounding, but low-single-digit organic guide.
Exponential Potential
3/10 · Low
A mature specialty insurer; no acceleration, no large-TAM optionality — a compounder, not an exponential.
⚖ Reverse-DCF cross-check Market-implied growth ≈ 15%/yr To justify today’s $279, earnings would have to compound roughly 15% a year for 10 years (9% discount rate). Analysts forecast ~15%/yr, so the market is pricing in about what the Street expects.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Assurant sells the protection plans and warranties you get when you buy a phone, a car, or rent an apartment — plus insurance that mortgage lenders buy to cover homes when a borrower's own policy lapses. It's a boring, steady, cash-generating business. Two-thirds of profit comes from the phone/car/warranty side (they call it "Global Lifestyle"), and the rest from housing insurance, which can get hit hard in a bad hurricane year.

Is the stock cheap or expensive? Cheap on the fundamentals — you pay about $14 for every $1 of annual profit, well below the market — but the price has run up a lot recently and sits right at its 12-month high, so you'd be buying at the top of the range. Our verdict is Watch: a good company, fairly priced, better bought on a dip than chased here.

Here's what our three scores mean in everyday terms:

The one big worry: a severe hurricane or catastrophe season can blow a hole in the housing-insurance results and the stock in any given quarter. Management even reports earnings "excluding catastrophes" precisely because that line is so lumpy.


Price & moving averages 12 months · 50 & 200-day averages · 52-week range

177204232260287Jul '25Sep '25Nov '25Feb '26Apr '26Jul '2652w hi $279Price 27950-DMA 251200-DMA 23152w lo $185

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

164195226257288Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26Price 27920-day avg 262

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

705030Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26RSI 76.0

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 76.

MACD 12 / 26 / 9 · trend & momentum

0Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26MACD 6.4signal 5.3

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago

86102118134150Jul '25Sep '25Nov '25Feb '26Apr '26Jul '26AIZ 146S&P 500 120XLF (sector) 106

Solid = AIZ · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

0491317$10BFY21EPS $9$10BFY22EPS $11$12BFY23EPS $15$12BFY24EPS $16$13BFY25EPS $20$14BFY26EEPS $21$15BFY27EEPS $22$15BFY28EEPS $24

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$279.48
Market cap$14B
P/E trailing12×
P/E FY26E / FY27E13× / 12×
EV / Sales1.1×
EV / EBITDA9.0×
Gross margin77.8%
Net margin7.6%
Dividend yield1.23%
Beta0.569
52-wk range$185 – $279
RSI(14)78
50 / 200-DMA$251 / $231
12-mo return+41% (SPY +21%)
Street target$286 ($246–$310)
Analyst grades11 Buy · 7 Hold · 1 Sell
FMP ratingA
Next earnings2026-08-05

What the experts actually said 0 traceable claims on AIZ · showing the highest-conviction voices

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Assurant, Inc. (NYSE: AIZ) is a ~130-year-old (founded 1892, formerly Fortis) global specialty insurer and protection-products company headquartered in Atlanta, ~14,200 employees. It runs two reporting segments today:

Revenue mix (FY2025, FMP product segmentation):

The strategic story management tells is Global Lifestyle scaling (subscriber growth in mobile protection, trade-in volumes, a growing US extended-service-contract program, and auto) funding buybacks and a rising dividend, while Housing is run for cash with catastrophe risk actively reinsured.

2. The expert thesis

There is no expert coverage of AIZ in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top array is empty. No podcast, letter, or analyst in our distilled panel has made a traceable, dated claim on Assurant.

What this means for the verdict. Per Synthos house rules, we do not fabricate conviction. Every name that enters on the conviction track cites real claim_id values; AIZ has none to cite. So this note is explicitly fundamentals- and quant-driven: the scores, cases, and verdict below are built entirely from FMP financials, analyst estimates, the SEC 8-K guidance, and the technicals — not from expert sentiment. Treat the absence of coverage as a breadth signal (nobody we track is banging the table here, in either direction), not as a hidden bull or bear case.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score0–10The read
Downside Risk (lower = safer)4 · Low-ModerateCheap (14× trailing, 9× EV/EBITDA), beta 0.57, net-debt/EBITDA 0.38×, ROE 17% — structurally sturdy. Offsets: RSI 78 at the 52-wk high (stretched entry) and Housing catastrophe tail risk.
Growth Quality6 · Solid~12% forward EPS CAGR (FY25 $17.29 → FY28E $24.41), but a chunk is buyback-driven and management guides only low-single-digit adjusted EPS growth ex-cat for 2026. Steady Lifestyle compounding, 17% ROE, but not a high-growth engine.
Exponential Potential3 · LowMature specialty insurer. Growth is not accelerating (revenue +15% FY23 → +8% FY25), the TAM is incremental, and at a $13.8B cap there is no large-TAM optionality. A durable compounder, not a multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.

CaseKey assumptionsFair value
BullLifestyle keeps compounding double-digit EBITDA; a benign catastrophe year lets Housing earnings drop through; buybacks continue. FY27E EPS beats to ~$24; the market re-rates a proven, low-beta compounder to ~15×.~$355 (+27%)
Base (our anchor)Estimates roughly hit — FY27E EPS ~$22.4; a steady ~12% EPS compounder with 17% ROE holds its current ~13× forward multiple.~$290 (+4%)
BearA severe catastrophe season hits Housing; Lifestyle growth stalls; the multiple de-rates on a cyclical/cat scare. FY26–27 EPS misses toward ~$18–19; multiple compresses to ~11–12×.~$220 (−21%)

Synthos fair value = the base case, ~$290 (+4%), with the full $220–$355 span as the honest range. This anchor sits almost exactly at the Street's $285.83 consensus — appropriate for a fairly-valued, well-covered name where we have no differentiated expert edge. This is a tracked call — the Forecaster Scorecard grades it once it matures. The thin upside to base fair value is exactly why the verdict is Watch, not Buy.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). AIZ is a decent compounder with essentially no exponential character:

Exponential Potential: Low (3/10). Own AIZ, if at all, for cheap, low-beta, ~10% total-return compounding (mid-single-digit EPS growth + buyback + ~1.2% yield), not for a fast multibagger. This honest framing is why it sits in a value/satellite sleeve, not a growth or degen tier.

5. Financials (real numbers — FMP annual/quarterly)

6. Valuation — cheap, and that's the point

On the numbers AIZ is inexpensive: 14× trailing EPS, ~13× FY26E, ~12× FY27E, 9.0× EV/EBITDA, 1.1× EV/sales, 2.4× P/B, and a ~10.5% FCF yield. For a business earning a 17% ROE with a fortress balance sheet, that is a reasonable-to-cheap multiple — the FMP letter rating is "A" (overall score 4/5). The PEG-style tension: ~12% forward EPS growth against a ~13× forward multiple is fair value, not a screaming bargain, especially once you discount the buyback-aided portion of EPS growth.

The problem is not the multiple — it's entry timing and thin upside. The stock is up +41% over 12 months, sits at a fresh 52-week high, and our base-case fair value (~$290) is only ~4% above spot and essentially on top of the Street's $285.83 consensus (high $310 / low $246). You're paying a fair price for a fair company at the top of its recent range. Street targets (context): consensus $285.83 — we anchor at ~$290, deliberately close, because we hold no differentiated expert edge here (KB breadth 0). A fairly-valued compounder at the high = Watch.

7. Technicals (from the tech block)

8. Moat & competitive position

Assurant's edge is embedded distribution and scale in niche protection lines, not brand or a patent. In Global Lifestyle it is deeply integrated into carrier, retailer, and OEM workflows (device protection, trade-in logistics, extended-service programs) — switching costs and operational complexity make it sticky for partners. In Global Housing it is a share leader in lender-placed insurance, a specialized, regulated niche with few credible competitors and high barriers (tracking systems, regulatory relationships). The moat is narrow but real; the risks to it are partner concentration (large carrier/retailer relationships), pricing cycles, and catastrophe/reinsurance costs.

Peer set (FMP, market cap ~$9–14B mid-cap financials): American Financial Group (AFG, $11.9B), Globe Life (GL, $14.0B), Old Republic (ORI, $10.2B), Reinsurance Group of America (RGA, $14.5B), plus non-insurers FMP lists as comps — FactSet (FDS), SEI (SEIC), Comerica (CMA), First Horizon (FHN), Invesco (IVZ), Jefferies (JEF). The insurance peers are the honest comparison; AIZ's specialty/protection niche and Lifestyle growth engine differentiate it from vanilla P&C or life carriers. It trades in line with the group on earnings, at a premium on P/B (justified by its higher ROE and fee-like Lifestyle income).

9. Management, capital allocation & guidance

10. Catalysts & what to watch

Thesis tripwires (what would change the call): a major catastrophe season that impairs book value; two quarters of stalling Lifestyle EBITDA; loss of a large distribution partner; or a de-rating below ~11× on a cyclical scare (bear) — conversely, a pullback to the low-$250s with the fundamentals intact would flip this from Watch toward Buy — Tactical.

11. Key risks

12. Verdict, position sizing & monitoring

Watch. Assurant is a genuinely good, cheap, low-beta specialty insurer — 14× trailing, 9× EV/EBITDA, 17% ROE, net-debt/EBITDA 0.38×, ~10.5% FCF yield, a well-covered growing dividend, and a Global Lifestyle engine that compounds. In a vacuum that's a Buy-quality profile. But three things pull the verdict to Watch: (1) the base-case fair value (~$290) is only ~4% above spot and sits right on the Street's consensus — thin upside; (2) the stock is at its 52-week high with RSI ~78, a stretched entry; and (3) management itself guides only low-single-digit adjusted EPS growth for 2026, with the headline "record quarter" flattered by an easy catastrophe comparison. Good company, fair price, hot entry — wait for a better one.

This verdict is logged as a tracked Synthos call as of 2026-07-03 at $279.48.


Provenance & disclosures